Clinical effects of probiotics in cystic fibrosis patients

A systematic review

Stephanie Van Biervliet, Dimitri Declercq, Shawn Somerset

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cystic fibrosis (CF) is characterised by a build-up of thick, intransient mucus linings of the digestive and respiratory mucosa, which disrupts digestive system functioning and microbiota composition. In view of the potential for probiotics to enhance microbiota composition in other contexts, this study investigated the current evidence for probiotics as an adjunct to usual therapy for CF. Electronic clinical databases were interrogated for human randomised, controlled, intervention trials (1985–2015) testing the effects of probiotics on clinical endpoints in CF were reviewed. From 191 articles identified in initial searches, six studies met the critical inclusion criteria, and were reviewed in detail. These studies varied in size (n = 22 to 61) but were generally small and showed substantial diversity in protocol, specific probiotic species used and range of clinical outcomes measured. Probiotic administration showed beneficial effects on fecal calprotectin levels, pulmonary exacerbation risk, and quality of life indicators. In one study, such changes were associated with variations in gut microbiota composition. Despite encouraging preliminary results, the limited number of small and highly varied studies to date do not justify the addition of probiotics as an adjunct to current CF treatment protocols. Importantly, very minimal adverse effects of probiotics have been reported.

Original languageEnglish
Pages (from-to)37-43
Number of pages7
JournalClinical Nutrition ESPEN
Volume18
DOIs
Publication statusPublished - 1 Apr 2017
Externally publishedYes

Fingerprint

Probiotics
Cystic Fibrosis
Microbiota
Leukocyte L1 Antigen Complex
Respiratory Mucosa
Digestive System
Mucus
Clinical Protocols
Randomized Controlled Trials
Quality of Life
Databases
Lung

Cite this

Van Biervliet, Stephanie ; Declercq, Dimitri ; Somerset, Shawn. / Clinical effects of probiotics in cystic fibrosis patients : A systematic review. In: Clinical Nutrition ESPEN. 2017 ; Vol. 18. pp. 37-43.
@article{1fc4df4b576047719d967767d7f1d993,
title = "Clinical effects of probiotics in cystic fibrosis patients: A systematic review",
abstract = "Cystic fibrosis (CF) is characterised by a build-up of thick, intransient mucus linings of the digestive and respiratory mucosa, which disrupts digestive system functioning and microbiota composition. In view of the potential for probiotics to enhance microbiota composition in other contexts, this study investigated the current evidence for probiotics as an adjunct to usual therapy for CF. Electronic clinical databases were interrogated for human randomised, controlled, intervention trials (1985–2015) testing the effects of probiotics on clinical endpoints in CF were reviewed. From 191 articles identified in initial searches, six studies met the critical inclusion criteria, and were reviewed in detail. These studies varied in size (n = 22 to 61) but were generally small and showed substantial diversity in protocol, specific probiotic species used and range of clinical outcomes measured. Probiotic administration showed beneficial effects on fecal calprotectin levels, pulmonary exacerbation risk, and quality of life indicators. In one study, such changes were associated with variations in gut microbiota composition. Despite encouraging preliminary results, the limited number of small and highly varied studies to date do not justify the addition of probiotics as an adjunct to current CF treatment protocols. Importantly, very minimal adverse effects of probiotics have been reported.",
keywords = "Cystic fibrosis, Inflammation, Probiotics, Systematic review, Cystic Fibrosis/drug therapy, Humans, Probiotics/administration & dosage",
author = "{Van Biervliet}, Stephanie and Dimitri Declercq and Shawn Somerset",
note = "Copyright {\circledC} 2017 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.clnesp.2017.01.007",
language = "English",
volume = "18",
pages = "37--43",
journal = "Clinical Nutrition ESPEN",
issn = "2405-4577",
publisher = "Elsevier Limited",

}

Clinical effects of probiotics in cystic fibrosis patients : A systematic review. / Van Biervliet, Stephanie; Declercq, Dimitri; Somerset, Shawn.

In: Clinical Nutrition ESPEN, Vol. 18, 01.04.2017, p. 37-43.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical effects of probiotics in cystic fibrosis patients

T2 - A systematic review

AU - Van Biervliet, Stephanie

AU - Declercq, Dimitri

AU - Somerset, Shawn

N1 - Copyright © 2017 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Cystic fibrosis (CF) is characterised by a build-up of thick, intransient mucus linings of the digestive and respiratory mucosa, which disrupts digestive system functioning and microbiota composition. In view of the potential for probiotics to enhance microbiota composition in other contexts, this study investigated the current evidence for probiotics as an adjunct to usual therapy for CF. Electronic clinical databases were interrogated for human randomised, controlled, intervention trials (1985–2015) testing the effects of probiotics on clinical endpoints in CF were reviewed. From 191 articles identified in initial searches, six studies met the critical inclusion criteria, and were reviewed in detail. These studies varied in size (n = 22 to 61) but were generally small and showed substantial diversity in protocol, specific probiotic species used and range of clinical outcomes measured. Probiotic administration showed beneficial effects on fecal calprotectin levels, pulmonary exacerbation risk, and quality of life indicators. In one study, such changes were associated with variations in gut microbiota composition. Despite encouraging preliminary results, the limited number of small and highly varied studies to date do not justify the addition of probiotics as an adjunct to current CF treatment protocols. Importantly, very minimal adverse effects of probiotics have been reported.

AB - Cystic fibrosis (CF) is characterised by a build-up of thick, intransient mucus linings of the digestive and respiratory mucosa, which disrupts digestive system functioning and microbiota composition. In view of the potential for probiotics to enhance microbiota composition in other contexts, this study investigated the current evidence for probiotics as an adjunct to usual therapy for CF. Electronic clinical databases were interrogated for human randomised, controlled, intervention trials (1985–2015) testing the effects of probiotics on clinical endpoints in CF were reviewed. From 191 articles identified in initial searches, six studies met the critical inclusion criteria, and were reviewed in detail. These studies varied in size (n = 22 to 61) but were generally small and showed substantial diversity in protocol, specific probiotic species used and range of clinical outcomes measured. Probiotic administration showed beneficial effects on fecal calprotectin levels, pulmonary exacerbation risk, and quality of life indicators. In one study, such changes were associated with variations in gut microbiota composition. Despite encouraging preliminary results, the limited number of small and highly varied studies to date do not justify the addition of probiotics as an adjunct to current CF treatment protocols. Importantly, very minimal adverse effects of probiotics have been reported.

KW - Cystic fibrosis

KW - Inflammation

KW - Probiotics

KW - Systematic review

KW - Cystic Fibrosis/drug therapy

KW - Humans

KW - Probiotics/administration & dosage

UR - http://www.scopus.com/inward/record.url?scp=85013482347&partnerID=8YFLogxK

U2 - 10.1016/j.clnesp.2017.01.007

DO - 10.1016/j.clnesp.2017.01.007

M3 - Article

VL - 18

SP - 37

EP - 43

JO - Clinical Nutrition ESPEN

JF - Clinical Nutrition ESPEN

SN - 2405-4577

ER -